36results about "Enkephalins" patented technology

Provided herein are antibodies and antigen binding fragments thereof specific to BCG antigen Ag85B as well as chimeric antigen receptors and lymphocytes comprising Ag85B antibodies as described and methods of treating cancer and tuberculosis infections using the CAR lymphocytes described. In a first aspect, provided herein is an isolated antibody or antigen binding fragment thereof capable of binding Bacillus Calmette-Guerin (BCG) antigen Ag85B.

The disclosure provides Tn epitope-specific chimeric antigen receptors and scFvs, including soluble scFvs and multimeric scFvs, as well as methods of identifying cancer subjects and cancer subject sub-populations amenable to anti-Tn immunotherapy and methods of treating cancer.

The present disclosure, relates, in general to analogs of proline-rich polypeptide 1 (PRP-1) designated tyrosine peptides (TYR peptide) that are useful to treat cancer, such as sarcomas, carcinomas and leukemias or liquid cancers.

This application provides a composition containing PENK protein and its application in promoting osteoblast osteogenic differentiation. Compared with the prior art, this application has the following advantages: The pro-PENK recombinant protein and the PENK-containing composition provided in this application, after being applied to cells with osteogenic potential, enhance osteogenic performance through interaction with CBFB protein, and can significantly promote osteogenic differentiation. Compared with the existing bone morphogenetic protein 2 (BMP recombinant protein), the osteogenic effect is superior. Furthermore, experiments have verified that the osteogenic differentiation effect of pro-PENK recombinant protein on osteoblasts is dose-dependent. This application further verifies that the combined use of low doses of PENK recombinant protein and BMP recombinant protein has a more significant cellular osteogenic effect than the use of either at high doses alone.

Provided herein are methods of using modified caveolin-1 (Cav-1) peptides to treat or prevent a kidney disease or disorder in a subject. In particular, provided are methods of using the modified Cav-1 peptides for the treatment of chronic kidney disease characterized by fibrosis, such as, for example, Alport syndrome.

The present invention provides delivery vectors for transferring a nucleic acid sequence to a cell in vitro, ex vivo or in vivo. The present invention provides methods of delivering a nucleic acid sequence to a cell and methods of treating focal epilepsies.

Artificial expression constructs for the rescue of voltage-gated sodium channel function using intein-mediated reconstitution of the SCN1A encoded protein, voltage-gated sodium channel alpha subunit 1 (Nav1.1) are described. Rescued voltage-gated sodium channel function can be used to treat disorders such as epilepsy, and more particularly, Dravet Syndrome.

The invention(s) disclosed herein relate to improved methods for expanding cell populations, particularly B cell populations. The invention further relates comprising improved cell media, compositions thereof, and methods of using such expanded B cells.

Embodiments of the disclosure include methods and compositions for producing T cell receptor (TCR) polypeptides specific for hematological neoantigens. In specific embodiments, T cells directed to one or more hematological neoantigens are produced following exposure of PBMCs to peptides that encompass one or more neoantigens, and the TCRs in the produced T cells are tested for efficacy and identified. The neoantigen-specific TCRs are utilized in a variety of immunotherapies.

Artificial expression constructs for the rescue of voltage-gated sodium channel function using intein-mediated reconstitution of the SCN1A encoded protein, voltage-gated sodium channel alpha subunit 1 (Nav1.1) are described. Rescued voltage-gated sodium channel function can be used to treat disorders such as epilepsy, and more particularly, Dravet Syndrome.

Compositions and methods for improved ACT are provided. Chimeric γδTCR cells including gamma-delta TCRs fused with an immunoglobulin antigen-binding domain targeting the Fc of human monoclonal antibodies (hmAb) are described. Compositions of chimeric γδTCR cells together with hmAbs that target antigen associated with a disease or disorder are described for selective ACT directed against the disease or disorder. The chimeric γδTCRs include removable masking domains that prevents non-specific T cell killing and reduce toxicity in vivo. Typically, the masking domain is removed by protease present in the TME. The compositions and methods provide enhanced ACT for cancer, auto-immune disease and other disease and disorders. Also disclosed are hmABs, genetically modified cells and pharmaceutical compositions and methods of use thereof for treating subjects having diseases or disorders.

The invention provides a genetically modified non-human animal. The genetically modified non-human animal comprises exogenous gamma and delta T cell receptor variable gene coding fragments in a genome of the genetically modified non-human animal; as well as tissues, embryos and cells thereof. Also provided are constructs and methods for making the genetically modified non-human animals. Human T cell receptor (TCR) cloning and library analysis are also included. The use of the animals for infectious diseases is also provided.

PD1-4-1BBL variant fusion proteins are provided. Also provided are isolated polypeptides comprising a PD1 variant or a 4-1BBL variant. Also provided are polynucleotides and nucleic acid constructs encoding the PD1-4-1BBL fusion protein or the isolated polypeptide, host-cells expressing the same and methods of use thereof.

The invention provides a composition containing PENK protein and application of the composition in promoting osteogenic differentiation by osteoblasts. Compared with the prior art, the proenkephalin PENK recombinant protein and the composition containing PENK have the advantages that after being applied to cells with osteogenic potential, the proenkephalin PENK recombinant protein and the composition containing PENK interact with CBFB protein to improve osteogenic performance, the effect of promoting osteogenic differentiation can be obviously achieved, and the proenkephalin PENK recombinant protein and the composition containing PENK have good application prospects. Compared with existing bone morphogenetic protein 2 (BMP) recombinant protein, the proenkephalin PENK recombinant protein is more excellent in osteogenesis promoting effect, and experiments prove that the osteogenic differentiation promoting effect of the proenkephalin PENK recombinant protein is dose-dependent. The application further verifies that the combined use of low doses of the PENK recombinant protein and the BMP recombinant protein has a more remarkable cell osteogenesis promoting effect compared with the independent use of high doses of the PENK recombinant protein and the BMP recombinant protein.

Expression vectors, preferably mRNA expression vectors, encoding for soluble ICAM-1 for increasing ICAM-1 levels in a subject in need thereof, as decoy receptor proteins for endogenous transmembrane ICAM-1. Therapeutic or prophylactic formulations of the same. Therapeutic or prophylactic treatment methods using the same, such that the administration of the composition results in expression, translation, and / or activity of the protein encoded by the expression vector in the subject, wherein the protein is soluble ICAM-1. Uses of mRNA expression vectors to deliver soluble ICAM-1 for both the prevention and treatment of RSV to reduce RSV disease severity and prevent death from viral infection.

The present disclosure provides modified immune cells or precursors thereof (e.g. T cells) comprising a first chimeric antigen receptor (CAR) capable of binding human IL13Rα2, a second CAR capable of binding EGFR or an isoform thereof, and a dominant negative TGFbβ type II receptor (DN-TGFbβRII). Compositions and methods of treatment are also provided.

The invention provides a. genetically modified non-human animal that comprises in its genome foreign γ and δ T cell receptor variable gene coding fragments, as well as its tissues, embryos, and cells. Also provided are constructs and methods for making said genetically modified non-human animal. Human T cell receptor (TCR) cloning and repertoire analysis are also included. Applications for using said animal in infectious diseases are also provided.

Subject matter of the present invention is a delivery vector comprising a DNA sequence encoding pre-prodynorphin or pre-prodynorphin-variants and wherein said delivery vector drives expression of a pre- propeptide in a target cell, and wherein said delivery vector comprising said DNA sequence enables the release of dynorphin or dynorphin-variants from the target cell on demand, and wherein said pre- propeptide is pre-prodynorphin or a pre-prodynorphin-variant and wherein said pre-propeptide comprises a signal peptide, wherein the signal peptide is a N-terminal extension of nascent polypeptide chains and wherein said signal peptide mediates protein targeting to the lumen of the endoplasmatic reticulum, and, wherein said pre-propeptide comprises a N-terminal pro-peptide fragment on the C- terminal end of said signal peptide and wherein said N-terminal pro-peptide fragment i) comprises a sorting motif comprising the elements DL and EXyL, in particular a sorting motif consisting of the amino acid sequence DLXxEXyL or comprises ii) a sorting motif of a pre-pro-neuropeptide or protein sorted to large dense core vesicles, other than pre-prodynorphin, as defined herein, where in certain embodiments x is an integer from 1 to 20, y is an integer from 1 to 10, and each instance of X may independently be any amino acid, and wherein said N-terminal pro-peptide fragment consists of 16 to 90 amino acids, as well as corresponding peptides, DNA molecules viral vectors and particles comprising any of these.

Disclosed are, inter alia, combinations comprising a first antisense (e.g., first double stranded RNAi (dsRNAi)) agent for inhibiting expression of proprotein convertase subtilisin kexin 9 (PCSK9), for example, human PCSK9, and a second antisense agent (e.g., second dsRNAi agent) for inhibiting expression of angiotensinogen (AGT); pharmaceutical compositions including the same, and methods of treatment using the same.

The present disclosure provides modified immune cells or precursors thereof (e.g. T cells) comprising a first chimeric antigen receptor (CAR) capable of binding human IL13Rα2, a second CAR capable of binding EGFR or an isoform thereof, and a dominant negative TGFbβ type II receptor (DN-TGFbβRII). Compositions and methods of treatment are also provided.

Described herein are compositions and methods for treating cancer in a subject. In some embodiments, the compositions and methods may be used for treating solid tumor cancers. In some embodiments, the compositions and methods may comprise a modified macrophage or monocyte comprising a surface-expressed phosphatidylserine (PS)-targeted chimeric antigen receptor (CAR) polypeptide to specifically target solid tumors. The modified macrophage or monocyte comprising the surface-expressed PS-targeted CAR polypeptide may activate an immune response in a tumor microenvironment in the subject, thereby treating the cancer in the subject.

The subject matter of the present invention is a delivery vector comprising a DNA sequence encoding pro-predynorphin or a variant of pro-predynorphin and wherein said delivery vector drives the expression of pro-predynorphin in a target cell and wherein said delivery vector comprising said DNA sequence is capable of releasing predynorphin or a variant of predynorphin from a target cell as needed, and wherein the pro-pro-peptide is pro-pro-peptide or a pro-pro-peptide variant and wherein the pro-pro-peptide comprises a signal peptide wherein the signal peptide is an N-terminal extension of a neonatal polypeptide chain and wherein the signal peptide mediates a protein targeting an endoplasmic network lumen, and wherein the pro-peptidogen comprises an N-terminal pro-peptidogen fragment on the C-terminus of the signal peptide and wherein the N-terminal pro-peptidogen fragment (i) comprises a sorting motif comprising elements DL and EXyL, in particular a sorting motif consisting of the amino acid sequence DLXxEXyL, or comprising ii) a sorting motif of pro-neuropeptidic or protein sorted into a dense core macrovesicle, except for pro-prodynorphin as defined herein, where in certain embodiments, x is an integer from 1 to 20, y is an integer from 1 to 10, and each instance of X may independently be any amino acid, such as any amino acid, or any amino acid, such as any amino acid, or any amino acid, such as any amino acid, or any amino acid, such as any amino acid, or any amino acid, such as any amino acid, or any amino acid, such as any amino acid, or any amino acid. And wherein the N-terminal pro-peptidic fragment consists of 16 to 90 amino acids, as well as corresponding peptides, DNA molecular viral vectors and particles comprising any of these.

The present disclosure provides a modified immune cell or a precursor thereof (e.g., a T cell) comprising a first chimeric antigen receptor (CAR) capable of binding to human IL13R [alpha] 2, a second CAR capable of binding to EGFR or an isoform thereof, and a dominant negative TGFRII receptor (DN-TGFRII). Compositions and methods of treatment are also provided.

Peptides are provided consisting of L- and / or D-amino acids and combinations thereof, which affect myeloid cells by action on the triggering receptors expressed on myeloid cells (TREMs), including TREM-1 and TREM-2. The peptides act on the TREM / DAP-12 signaling complex. Also provided are lipid and sugar conjugated peptides comprising L- or D-amino acids. A method is provided of designing the peptides and lipid- and / or sugar-conjugated peptides comprising L- or D-amino acids. The disclosure relates to the therapy of various myeloid cell-related disease states involving the use of these peptides and compounds. The peptides and compounds are useful in the treatment and / or prevention of a disease or condition where myeloid cells are involved or recruited. The peptides of the present invention also are useful in the production of medical devices comprising peptide matrices (for example, medical implants and implantable devices).

Disclosed herein are novel polynucleotide variants of KCVN2, voltage-gated potassium ion channel polypeptides encoded by them and their uses, for example, in methods of restoring photoreceptor functions and treating a subject with a retinal disorder, such as CDSRR.

The present invention relates to chimeric antigen receptors (CAR) containing TCR hinge and transmembrane domains. The present invention also relates to using transmembrane pairing to enhance the stability and specificity of dual antigen CARs. The present invention also relates to new CARs containing transmembrane and signaling domains from cytokine receptors.